Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Income from Continuing Operations rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 14415.3%. This contributed to the annual value of -$64.0 million for FY2024, which is 1594.04% down from last year.
  • Per Theravance Biopharma's latest filing, its Income from Continuing Operations stood at $3.6 million for Q3 2025, which was up 12846.91% from $54.8 million recorded in Q2 2025.
  • Theravance Biopharma's Income from Continuing Operations' 5-year high stood at $54.8 million during Q2 2025, with a 5-year trough of -$79.7 million in Q1 2021.
  • In the last 5 years, Theravance Biopharma's Income from Continuing Operations had a median value of -$15.6 million in 2023 and averaged -$21.7 million.
  • As far as peak fluctuations go, Theravance Biopharma's Income from Continuing Operations crashed by 17144.54% in 2024, and later soared by 43175.03% in 2025.
  • Theravance Biopharma's Income from Continuing Operations (Quarter) stood at -$57.8 million in 2021, then surged by 75.35% to -$14.2 million in 2022, then skyrocketed by 40.23% to -$8.5 million in 2023, then tumbled by 171.45% to -$23.1 million in 2024, then skyrocketed by 115.65% to $3.6 million in 2025.
  • Its Income from Continuing Operations was $3.6 million in Q3 2025, compared to $54.8 million in Q2 2025 and -$13.5 million in Q1 2025.